<div id="readability-page-1"><p>Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA - Get Free Report) shares shot up 3.6% during mid-day trading on Tuesday . The stock traded as high as $1.7650 and last traded at $1.72. 9,959 shares were traded  during mid-day trading, a decline of 53% from the average session volume of 21,379 shares. The stock had previously closed at $1.66.</p><div><p><span></span><span>Get <strong>Innate Pharma</strong> alerts:</span></p></div><h2>Analysts Set New Price Targets</h2><p>A number of analysts have weighed in on the stock. BTIG Research  restated a &#34;buy&#34; rating and set a $8.00 price objective on shares of Innate Pharma in a research note on Wednesday, October 29th. Weiss Ratings  reiterated a &#34;sell (e+)&#34; rating on shares of Innate Pharma in a research note on Thursday, January 22nd. Finally, HC Wainwright  set a $5.00 price target on shares of Innate Pharma and gave the company a &#34;buy&#34; rating in a research report on Wednesday, October 29th. One equities research analyst  has rated the stock with a Strong Buy rating, one  has given a Buy rating, one  has issued  a Hold rating and one  has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $5.00.</p><p><b>Read Our Latest Analysis on IPHA</b></p><h2>Innate Pharma Stock Up 3.6%</h2><p>The business's 50 day moving average price is $1.75 and its 200 day moving average price is $1.91. </p><h2>Institutional Investors Weigh In On Innate Pharma</h2><p>A number of hedge funds have recently added to or reduced their stakes in IPHA. Jane Street Group LLC purchased a new position in shares of  Innate Pharma in the 4th quarter worth $162,000.  Millennium Management LLC purchased a new stake in  Innate Pharma during the fourth quarter valued at $36,000.  Finally, OLD Mission Capital LLC bought a new position in  Innate Pharma in the fourth quarter valued at about $50,000. 0.16% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>About Innate Pharma</h2> (Get Free Report)<p>Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body's innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.  </p><p>The company's lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Innate Pharma</li><li>The gold chart Wall Street is terrified of…</li><li>America’s 1776 happening again</li><li>Buy this Gold Stock Before May 2026</li><li>What a Former CIA Agent Knows About the Coming Collapse</li><li>This makes me furious</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Innate Pharma Right Now?</h2><p>Before you consider Innate Pharma, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Innate Pharma wasn't on the list.</p><p>While Innate Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

IPHA

IBBQ

SBIO

<p>Innate Pharma (NASDAQ:IPHA) shares rose 3.6% to $1.72 during mid-day trading, despite a 53% decline in trading volume. Analysts have mixed opinions, with BTIG Research maintaining a "buy" rating and a price target of $8.00, while Weiss Ratings issued a "sell" rating. The stock has an average rating of "Moderate Buy" and a target price of $5.00. Institutional investors have recently increased their stakes in the company, which focuses on developing antibody-based therapies for cancer treatment.</p>

Innate Pharma (NASDAQ:IPHA) Shares Up 3.6% - Here's What Happened